BSRBR-RA – Review of 2025! 2025 was another good year for BSRBR-RA. As always, we are very grateful to the NHS professionals who provide data, and to the participants, especially those who have completed follow up questionnaires. BSRBR-RA are proud to have had a wide...
Have you ever wondered what happens to the data that is collected as part of the BSRBR-RA Study? We have recently published a new data journey to help our participants to understand the impact that their data has had on the real world of rheumatology.Joining the...
2024 contributorsWith 600+ registrations and over 9000 follow ups completed last year, we wanted to thank our sites and acknowledge the hard work of our NHS healthcare professional colleagues. We are grateful to them for their diligence in providing the data that...
Data from the BSRBR-RA study has influenced clinical guidelines.
We recently held a workshop for our NHS healthcare professional colleagues involved in the BSRBR-RA Study around the topic of Recruitment. We wanted to find out what really works in terms of recruiting participants to the study and to share good practice across...
We recently launched our online system for collecting patient data. This is a new exciting development for us and we are thrilled that we have been able to start sending questionnaires to our study participants.How it worksThe participant consents to the study and...
Have you ever wondered where the data you provide are used?Whether you are a participant in the study, or an NHS professional who provides the data to BSRBR-RA, the answer is the same. This data is vital in the ongoing research into the long-term safety of biologic,...
2024 has been another great year for BSRBR-RA. We’re very grateful to the NHS professionals who provide data, and to the participants. The data provided is integral to the success of the research.Our year in numbersOur publications this year Association between body...
Dr Simon Tsoi investigated the association between body weight and tocilizumab effectiveness in rheumatoid arthritis, using data from the BSRBR-RA study. The results were published in the Rheumatology journal. What was already known?Tocilizumab is a type of treatment...
What is Tyenne? Tyenne is the first tocilizumab (interleukin-6) biosimilar that has recently been approved by the European Medicines Agency (EMA) for the treatment of moderate to severe rheumatoid arthritis in adults. It is now starting to be prescribed in the UK and...
+44 (0) 161 306 6000
Recent Comments